

25 February 2021

**ReNeuron Group plc**  
("ReNeuron" or the "Company")

## Appointment of Joint Broker

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Allenby Capital Limited ("Allenby") as joint corporate broker, with immediate effect to work alongside the Company's existing nominated adviser and joint broker, Stifel Nicolaus Europe Limited.

**Michael Hunt, Chief Financial Officer of ReNeuron, commented:** *"The Company is pleased to appoint Allenby as its joint corporate broker, which, together with the appointment of Walbrook PR as the Company's new investor relations and PR adviser, will further broaden our investor outreach activities, particularly with regards to private client brokers and retail investors."*

### Contacts:

#### ReNeuron

Olav Hellebø, Chief Executive Officer  
Michael Hunt, Chief Financial Officer

[www.reneuron.com/investors](http://www.reneuron.com/investors)

Via Walbrook PR

#### Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

#### Allenby Capital Limited (Joint Broker)

James Reeve/George Payne (Corporate Finance)  
Tim Sohal (Sales & Corporate Broking)

+44 (0)20 3328 5656

#### Walbrook PR (Media & Investor Relations)

Paul McManus, Alice Woodings

+44 (0)20 7933 8780 or [reneuron@walbrookpr.com](mailto:reneuron@walbrookpr.com)

+44 (0)7980 541 893 / +44 (0)7407 804 654

### About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit [www.reneuron.com](http://www.reneuron.com)